Management of HIV in resource limited settings

Current Opinion in Infectious Diseases

Volumn 22, Issue 5, 2009, Pages 464-470

  McCutchan, J Allen ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cryptococcal meningitis; HIV; International; Resource limited settings; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; FLUCONAZOLE; ISONIAZID; LAMIVUDINE; RIFAMPICIN; RIFAPENTINE; STAVUDINE; STREPTOMYCIN; TENOFOVIR;

CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DEVELOPED COUNTRY; DRUG DOSE COMPARISON; DRUG MEGADOSE; EPIDEMIC; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NONHUMAN; OPPORTUNISTIC INFECTION; REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; VIROTHERAPY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS;

EID: 70249148640     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283308fe2     Document Type: Review

References (16)

1. Smith DM, Schooley RT. Running with scissors: using antiretroviral therapy without monitoring viral load. Clin Infect Dis 2008; 46:1598-1600.
2. Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretro viral therapy. AIDS 2009; 23:1127-1134.
3. Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.
4. Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291-2302.
5. Marazzi MC, Liotta G, Germano P, et al. Excessive early mortality in the first year of treatment in HIV type 1-infected patients initiating antiretroviral therapy in resource-limited settings. AIDS Res Hum Retroviruses 2008; 24:555-560.
6. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
7. Martinson NBG, Msandiwa R, Moulton L, etal. Novel regimensfortreating latent TBin HIV-infected adults in South Africa: a randomized clinical trial. In: Proceedings of the 16th International Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 8-11 February 2009. Abstract 36bLB.
8. Valesco M, Castilla V, Sanz J. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-152.
9. Parkes-Ratanshi RKA, Wakeham K, Levin J, et al. Successful primary intervention of cryptococcal disease using fluconazole prophylaxis in HIV-infected Ugandan adults. In: Proceedings of the 16th International Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 8-11 February 2009. Abstract 32.
10. Kaplan JE, Benson C, Holmes KH, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
11. Cohen DZE, MukakaM, ReissM, etal. Distinguishing features of cryptococcal and tuberculosis meningitis in adults in Malawi. In: Proceedings of the 16th International Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 8-11 February 2009. Abstract 791.
12. Makadzange ANC, Takarinda K, Reid M, et al. Early vs delayed ART in the treatment of cryptococcal meningitis in Africa. 16th International Con ference on Retroviruses and Opportunistic Infections; Montreal, Canada; 8-11 February 2009. Abstract 36cLB.
13. Zolopa A, Andersen J, Komarow L, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunis tic infections: a multicenter randomized strategy trial. PLoS One 2009;4:e5575.
14. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47:1556-1561.
15. Manosuthi WCP, Sungkanuparph S, Anekthananon T, et al. Serum and cerebrospinal fluid concentration monitoring for high-dose fluconazole in HIV-associated cryptococcal meningitis-infected patients. In: Proceedings of the 16th International Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 8-11 February 2009. Abstract 792.
16. Boulware DMD, Bergemann T, Shuli B, et al. Inflammatory biomarkers in serum predict HIV immune reconstitution inflammatory syndrome and death after cryptococcal meningitis. 16th International Conference on Retroviruses and Opportunistic Infections; Montreal, Canada; 8-11 February 2009. Abstract 774.